Cyclacel Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of September 2024: -55.36%

Cyclacel Pharmaceuticals Inc (CYCC) has an Asset Resilience Ratio of -55.36% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CYCC current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

$-2.98 Million

Cash + Short-term Investments

Total Assets

$5.38 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2003–2018)

This chart shows how Cyclacel Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See CYCC book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Cyclacel Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Cyclacel Pharmaceuticals Inc worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$-2.98 Million	-55.36%
Total Liquid Assets	$-2.98 Million	-55.36%

Asset Resilience Insights

Limited Liquidity: Cyclacel Pharmaceuticals Inc maintains only -55.36% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Cyclacel Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Cyclacel Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	25.67%
Tubize-Fin BR:TUB	Biotechnology	0.05%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
Dashenlin Pharm Grp Co Ltd SHG:603233	Biotechnology	0.02%
Staidson Beijing Biopharma SHE:300204	Biotechnology	7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	41.25%
Ardelyx Inc NASDAQ:ARDX	Biotechnology	41.14%
Xiangxue Pharmaceutical SHE:300147	Biotechnology	0.05%

Annual Asset Resilience Ratio for Cyclacel Pharmaceuticals Inc (2003–2018)

The table below shows the annual Asset Resilience Ratio data for Cyclacel Pharmaceuticals Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2018-12-31	0.33%	$66.00K	$19.82 Million	-0.17pp
2017-12-31	0.51%	$132.00K	$26.00 Million	-0.16pp
2016-12-31	0.67%	$132.00K	$19.66 Million	+0.14pp
2015-12-31	0.53%	$132.00K	$24.76 Million	+0.08pp
2014-12-31	0.45%	$132.00K	$29.39 Million	+0.08pp
2013-12-31	0.37%	$132.00K	$35.52 Million	-0.42pp
2012-12-31	0.79%	$153.00K	$19.35 Million	-75.73pp
2011-12-31	76.52%	$19.89 Million	$26.00 Million	-15.87pp
2010-12-31	92.39%	$29.07 Million	$31.46 Million	+87.54pp
2008-12-31	4.85%	$1.50 Million	$30.96 Million	-31.72pp
2007-12-31	36.58%	$27.77 Million	$75.91 Million	+21.15pp
2006-12-31	15.43%	$9.76 Million	$63.28 Million	-34.42pp
2005-12-31	49.85%	$10.69 Million	$21.45 Million	-10.26pp
2004-12-31	60.11%	$33.42 Million	$55.60 Million	-0.98pp
2003-12-31	61.08%	$11.30 Million	$18.50 Million	--

pp = percentage points

About Cyclacel Pharmaceuticals Inc

NASDAQ:CYCC USA Biotechnology

Market Cap

$14.25 Million

Market Cap Rank

#25987 Global

#5207 in USA

Share Price

$6.37

Change (1 day)

-5.98%

52-Week Range

$0.24 - $17.15

All Time High

$3671.65